Perspective Therapeutics Inc 2026年季度报告

FORM 10-Q For the quarterly period ended June 30, 2026OR For the transition period from __________ to ____________ Commission File Number: 001-33407 PERSPECTIVE THERAPEUTICS, INC.(Exact name of registrant as specified in its charter) Delaware41-1458152(State or other jurisdiction of incorporation ororganization)(I.R.S. EmployerIdentification No.) Registrant’s telephone number, including area code:(206) 676-0900 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ Number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date: ClassOutstanding as of August 5, 2026Common stock, $0.001 par value114,151,663 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS In addition to historical information, this Quarterly Report on Form 10-Q (Form 10-Q) contains certain “forward-lookingstatements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). This statement is included for theexpress purpose of availing Perspective Therapeutics, Inc. of the protections of the safe harbor provisions of the PSLRA. This Form 10-Q, including Management’s Discussion and Analysis of Financial Condition and Results of Operations in Part I, Item2, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the SecuritiesAct), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). All statements contained in thisForm 10-Q other than statements of historical fact, including, without limitation, statements regarding our future financialcondition, results of operations, business strategy and plans and objectives of management for future operations, industry trends andother future events are forward-looking statements. In some cases, you can identify forward-looking statements by terminology,such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “forecast,” “project,” “may,” “could,” “might,” “plan,” “should,”“will,” “would” or the negative of these terms and other similar expressions, although not all forward-looking statements containthese identifying terms. Forward-looking statements in this Form 10-Q include, among other things: •the timing, progress and results of our discovery programs, preclinical studies and clinical trials of our current andfuture product candidates, including statements regarding the timing of our planned regulatory communications,submissions and approvals, initiation and completion of studies or trials and related preparatory work and the periodduring which the results of the trials will become available;•our expectation that our manufacturing infrastructure will have the capacity to meet future clinical trial and commercialdemands at major treatment centers;•our belief regarding the geographic scope and depth of protection for our core radiopharmaceutical technologies andmanufacturing platforms;•our plans to expand our supply network and manufacturing and distribution capabilities;•our expectations regarding the potential functionality, capabilities and benefits of our product candidates, if approved,for commercial use;•our expectations regarding the potential size of the commercial market for our product candidates and other programs;•our expectations regarding the scope of any approved indication for any product candidate or other program;•our estimates of our expenses, ongoing losses, future revenue, capital requirements and our need for or abil